About Us
TheranosticTrials was developed through the collaboration of 2 key opinion leaders in the field of Radiopharmaceuticals. Drs. Luke Nordquist and Oliver Sartor saw the need for a such a web-based tool to provide patient education & ultimately improve access to the rapidly expanding field of radiopharmaceutical clinical trials. Patients globally are seeking access to these highly sought-after clinical trials which are providing new hope.
TheranosticTrials is a unique digital platform providing a comprehensive listing of all Radiopharmaceutical & Molecular Imaging trials by cancer type. In addition, pharmaceutical sponsors have the ability to upload and provide patient-centric educational material and trial details.
TheranosticTrials is a production of XCancer® Software, LLC which strives to increase clinical trial access and participation. Health disparities continues to plague cancer care globally. XCancer® views clinical trials and patient education as two key components in the fight against health care disparities and towards equality.
Dr. Luke Nordquist , the CEO of the Urology Cancer Center, GU Research Network & the XCancer® Organization has surfaced as a leader in the field of Radiopharmaceuticals and Molecular Imaging for Prostate Cancer. Dr. Luke is a practicing Medical Oncologist with an expertise in Prostate Cancer. His Community Cancer Center, located in Omaha, NE has rapidly gained international recognition for their participation in early and late phase trials of Ra223, Lu177, Ac225, Th227, Cu64, & Cu67. He was a lead accruing site for the ALSYMPCA and VISION Trials. His site was 1 of 3 early U.S. sites for Ac225 and Th227 trials.
Dr. Luke is also the CEO of the XCancer® Research Network, a network of Community Cancer Centers across the U.S., providing cancer clinical trials closer to home. Community Cancer Centers treat the vast majority of cancer patients yet historically, have not actively participated in clinical trials. XCancer® Research Network strives to change the paradigm by increasing Community Cancer Center participation and improved access for cancer patients. Several of the XCancer® Research sites actively participated in the VISION trial providing Lu177 closer to home. XCancer Health Physics Services is a consulting service for Community Cancer Centers interested in becoming a Theranostics center.
Dr. Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 400 peer-reviewed articles, led or co-led multiple national and international clinical studies, including three radiopharmaceutical phase III studies pivotal for FDA approval in prostate cancer (Samarium-153 EDTMP, Radium-223, and Lu-177-PSMA-617). He has lectured widely, and at last count has given invited lectures in 33 countries.
He is currently the Associate Dean for Oncology, Medical Director of the Tulane Cancer Center, and serves as the Laborde Professor for Cancer Research at Tulane Medical School with appointments in both the Medicine and Urology Departments. He is the Medical Oncology Chair of the GU committee of NRG, a national cancer research group. He is also a past member of the National Cancer Institute Board of Scientific Counselors (Clinical Sciences and Epidemiology).
